NEW YORK – Illumina and metagenomics technology firm IDbyDNA announced a strategic partnership and comarketing agreement on Tuesday.
The firms said in a statement that they aim to provide "a complete, streamlined workflow solution for infectious disease applications" of next-generation sequencing, providing pathogen identification as well as information on antimicrobial resistance markers.
Under the terms of the agreement, the partners will comarket IDbyDNA's Explify platform for use with Illumina's NGS instruments and library preparation kits.